SuperworthErasca market cap ERAS
Share price times shares outstanding: what the whole company sells for, since 2021.
- Today, Oct 23, 2026
- $5B
- Highest close in our data
- $6.7B
- Apr 2026
Erasca is worth $5B at the close on Oct 23, 2026, at $14.39 a share.
That is up 645% over the last year and up 110% over five years.
Its highest close in our data was $6.7B in Apr 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $5B | $1B | $6.7B | +410% |
| 2025 | $987.3M | $328.6M | $1B | +37% |
| 2024 | $718.1M | $255.3M | $887.1M | +123% |
| 2023 | $321.8M | $252.3M | $532.3M | −39% |
| 2022 | $527.4M | $501.7M | $1.6B | −72% |
| 2021 | $1.9B | $1.7B | $2.9B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Erasca's size, closest first, today.
| Company | Market cap |
|---|---|
| ERASErasca | $5B |
| KNSAKiniksa Pharmaceuticals International | $6B |
| LGNDLigand Pharmaceuticals | $6.1B |
| INDVIndivior Pharmaceuticals | $4.1B |
| ARQTArcutis Biotherapeutics | $3.9B |
| AMRXAmneal Pharmaceuticals | $6.5B |
| LQDALiquidia | $3.8B |
| OGNOrganon | $3.6B |
| ALKSAlkermes plc. | $7.3B |
| TGTXTG Therapeutics | $8.3B |
| PTGXProtagonist Therapeutics | $9B |
| Peer median | $6B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Erasca
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.